|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the utility of <sup>18</sup>F-FDG PET-CT in diagnosing extracardiac organ involvement in cases of CS.
|
31501049 |
2020 |
|
Cardiac sarcoidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty-seven CS patients (CS group), and 52 patients who underwent FDG PET/CT to detect malignant tumors with any FDG cardiac uptake (non-CS group) were studied.
|
30327855 |
2019 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Careful attention to FDG uptake would further elucidate CS pathophysiology and aid in the early treatment of VA.
|
31631075 |
2019 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of a 42-year-old Japanese man with ocular and pulmonary sarcoidosis who eventually led to a diagnosis with cardiac sarcoidosis (CS) through endomyocardial biopsy (EMB), despite negative findings on both late gadolinium enhancement with cardiac magnetic resonance (LGE-CMR) imaging and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET).
|
31773564 |
2019 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
11C-4DST PET/CT Imaging of Cardiac Sarcoidosis: Comparison With 18F-FDG and Cardiac MRI.
|
29538030 |
2018 |
|
Cardiac sarcoidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There is no identified level of FDG uptake in cardiac sarcoidosis (CS) associated with increased risk of arrhythmias, conduction disease, heart failure, or death.
|
30421379 |
2018 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac inflammation/infection imaging with 18F-FDG has been very useful in guiding patient management in conditions such as cardiac sarcoidosis, myocarditis, device infections, and prosthetic implant-related infections.
|
30238300 |
2018 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the use of image fusion between (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) and magnetic resonance imaging (MRI) to diagnose patients with cardiac sarcoidosis (CS).
|
27604109 |
2018 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this systematic review was to identify the optimal dietary prescription for suppression of physiological <sup>18</sup>F-FDG myocardial uptake to enhance clinical diagnosis of CS.
|
30088196 |
2018 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inter- and Intraobserver Agreement of <sup>18</sup>F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis.
|
28254873 |
2017 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis.
|
27457527 |
2017 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis.
|
28418949 |
2017 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac FDG uptake was classified as: "none" and "ringlike diffuse at base" (negative for CS), "focal" (positive for CS), and "diffuse" (indeterminate for CS).
|
27922863 |
2017 |
|
Cardiac sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When utilized in conjunction with other imaging modalities, such as echocardiography, PET F-FDG imaging can help distinguish between active cardiac sarcoidosis and other etiologies of nonischemic cardiomyopathy.
|
28263213 |
2017 |